BillionToOne

BillionToOne develops a single-molecule diagnostic platform powered by Quantitative Counting Templates (QCTs) to quantify sparse disease-causing DNA fragments in cell-free DNA at the single-base-pair level, enabling precise measurement for prenatal screening and cancer monitoring. Its Prenatal Unity Complete is the first non-invasive prenatal test that uses cfDNA from a single maternal blood draw at 9+ weeks to assess fetal risk for recessive conditions and aneuploidies. Its Northstar tests (Select and Response) provide a pan-cancer liquid biopsy to guide therapy selection and monitor treatment response in real time.

AI named BillionToOne from June 2026 to July 2026.